Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.77 |
| ▸ | MTOR | P42345 | 17/20 | 0.77 |
| ▸ | RPTOR | Q8N122 | 8/20 | 0.77 |
| ▸ | MLST8 | Q9BVC4 | 8/20 | 0.77 |
| ▸ | PIK3R1 | P27986 | 7/20 | 0.77 |
| ▸ | RICTOR | Q6R327 | 7/20 | 0.77 |
| ▸ | MAPKAP1 | Q9BPZ7 | 7/20 | 0.77 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.57 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.57 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.57 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.57 |
| ▸ | PRKDC | P78527 | 1/20 | 0.57 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.57 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16625646 | 1.00 | PIK3CA (0.77) | PIK3CAMTORRPTORMLST8PIK3R1 | |
| SCHEMBL18031211 | 0.87 | PIK3CA (1.00) | PIK3CAMTORRPTORMLST8PIK3R1 | |
| SCHEMBL16625604 | 0.87 | PIK3CA (1.00) | PIK3CAMTORRPTORMLST8PIK3R1 | |
| SCHEMBL16625599 | 0.87 | PIK3CA (1.00) | PIK3CAMTORRPTORMLST8PIK3R1 | |
| SCHEMBL18011614 | 0.82 | PIK3CA (0.75) | PIK3CAMTORRPTORMLST8PIK3R1 | |
| SCHEMBL18011613 | 0.82 | PIK3CA (0.75) | PIK3CAMTORRPTORMLST8PIK3R1 | |
| SCHEMBL16625878 | 0.82 | PIK3CA (0.75) | PIK3CAMTORRPTORMLST8PIK3R1 | |
| SCHEMBL16625876 | 0.82 | PIK3CA (0.75) | PIK3CAMTORRPTORMLST8PIK3R1 | |
| SCHEMBL16620463 | 0.79 | PIK3CA (0.80) | PIK3CAMTORRPTORMLST8PIK3R1 | |
| SCHEMBL20708101 | 0.79 | PIK3CA (0.80) | PIK3CAMTORRPTORMLST8PIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052504-B1 | CONFORMATIONALLY RESTRICTED PI3K AND MTOR INHIBITORS | UNIV BASEL (CH) | 2019-02-06 | — | — | EP | claimed |
| US-9556203-B2 | Conformationally restricted P13K and mTOR inhibitors | PIQUR THERAPEUTICS AG (CH) | 2017-01-31 | — | — | US | claimed |
| US-20160244463-A1 | CONFORMATIONALLY RESTRICTED P13K AND MTOR INHIBITORS | TORQUR AG (CH) | 2016-08-25 | — | — | US | claimed |
| EP-3052504-B1 | CONFORMATIONALLY RESTRICTED PI3K AND MTOR INHIBITORS | UNIV BASEL (CH) | 2019-02-06 | — | — | EP | disclosed |
| EP-3052504-B1 | CONFORMATIONALLY RESTRICTED PI3K AND MTOR INHIBITORS | UNIV BASEL (CH) | 2019-02-06 | — | — | EP | disclosed |
| US-9556203-B2 | Conformationally restricted P13K and mTOR inhibitors | PIQUR THERAPEUTICS AG (CH) | 2017-01-31 | — | — | US | disclosed |
| US-9556203-B2 | Conformationally restricted P13K and mTOR inhibitors | PIQUR THERAPEUTICS AG (CH) | 2017-01-31 | — | — | US | disclosed |
| US-9556203-B2 | Conformationally restricted P13K and mTOR inhibitors | PIQUR THERAPEUTICS AG (CH) | 2017-01-31 | — | — | US | disclosed |
| US-20160244463-A1 | CONFORMATIONALLY RESTRICTED P13K AND MTOR INHIBITORS | TORQUR AG (CH) | 2016-08-25 | — | — | US | disclosed |
| US-20160244463-A1 | CONFORMATIONALLY RESTRICTED P13K AND MTOR INHIBITORS | TORQUR AG (CH) | 2016-08-25 | — | — | US | disclosed |
| US-20160244463-A1 | CONFORMATIONALLY RESTRICTED P13K AND MTOR INHIBITORS | TORQUR AG (CH) | 2016-08-25 | — | — | US | disclosed |
| WO-2015049369-A1 | CONFORMATIONALLY RESTRICTED PI3K AND MTOR INHIBITORS | UNIVERSITAET BASEL (CH) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244463-A1 | CONFORMATIONALLY RESTRICTED P13K AND MTOR INHIBITORS | MTOR, RICTOR, PIK3R4 | PIK3CA 15/4885MTOR 1/4885RPTOR 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.